Literature DB >> 7840857

Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes.

I Bergerot1, N Fabien, V Maguer, C Thivolet.   

Abstract

Oral administration of porcine insulin has been shown to be effective in preventing the spontaneous occurrence of diabetes in the Non-Obese Diabetic (NOD) mouse model. In the present study, we demonstrate that feeding 6-week-old female mice with 20 units of human insulin every 2-3 days for 30 days induces an active mechanism of suppression through the generation of regulatory T cells. Adult irradiated NOD males i.v. injected with 5 x 10(6) T cells from the spleens of diabetic female donors and the same number of T cells from the spleens of insulin-fed animals had less successful diabetes transfer than controls (4/15 vs. 8/16, P < 0.001). Protection from clinical diabetes was associated with a reduction in severe insulitis (16.4 +/- 3.6% vs. 52.3 +/- 12.8%, P = 0.023). However, more than 85% of the islets were inflamed. Feeding animals for 15 days reduced the magnitude of this protection since the number of successful transfers after 1 month was comparable (12/17 vs. 14/17) despite a significant delay in diabetes onset (P < 0.001). No difference in the contribution of T cell subsets was noted by cytofluorometry in the spleens of treated animals. When T cell subsets from insulin-fed animals were co-injected with diabetogenic T cells, only purified CD4+ T cells were able to transfer protection since only 3/12 mice became diabetic after 36 days in comparison to 3/6 in the group co-injected with CD4+ T cells from PBS-fed animals, or 5/6 in the group injected with CD8+ T cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7840857     DOI: 10.1006/jaut.1994.1050

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  22 in total

Review 1.  Immunotherapy of immune-mediated diabetes. Present and future.

Authors:  N Maclaren
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 2.  Immune mechanisms that regulate susceptibility to autoimmune type I diabetes.

Authors:  B Singh; T L Delovitch
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

3.  Peptide-based treatment for autoimmune diseases: learning how to handle a double-edged sword.

Authors:  Alberto Pugliese
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

4.  Anti-GAD monoclonal antibody delays the onset of diabetes mellitus in NOD mice.

Authors:  V Menard; H Jacobs; H S Jun; J W Yoon; S W Kim
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

Review 5.  Oral tolerance and the treatment of rheumatoid arthritis.

Authors:  H L Weiner; Y Komagata
Journal:  Springer Semin Immunopathol       Date:  1998

Review 6.  Oral tolerance in disease.

Authors:  P Garside; A M Mowat; A Khoruts
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

Review 7.  Immune Mechanisms and Pathways Targeted in Type 1 Diabetes.

Authors:  Laura M Jacobsen; Brittney N Newby; Daniel J Perry; Amanda L Posgai; Michael J Haller; Todd M Brusko
Journal:  Curr Diab Rep       Date:  2018-08-30       Impact factor: 4.810

Review 8.  New and future immunomodulatory therapy in type 1 diabetes.

Authors:  James E Tooley; Frank Waldron-Lynch; Kevan C Herold
Journal:  Trends Mol Med       Date:  2012-02-17       Impact factor: 11.951

9.  Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside.

Authors:  Damien Bresson; Matthias von Herrath
Journal:  Diabetes Care       Date:  2009-10       Impact factor: 17.152

Review 10.  Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization.

Authors:  Peter Achenbach; Jennifer Barker; Ezio Bonifacio
Journal:  Curr Diab Rep       Date:  2008-04       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.